Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046443 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
A Phase 2 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT06046443 is a Phase 2 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT06046443, a Phase 2 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal of this study is to determine how well LB54640 works and how safe it is in patients with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older with HO. Patients will take an oral daily dose of either LB54640 (low, middle, or high dose) or placebo through Week 14. Eligible patients who consent to continue in the study after Week 14 will take an oral daily dose of LB54640 through Week 56.
Interventions
- DRUG Placebo
- DRUG LB54640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2026-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06046443
The ClinicalTrials.gov registry entry for NCT06046443 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06046443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06046443 about?
NCT06046443 is a clinical study titled "A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity". The goal of this study is to determine how well LB54640 works and how safe it is in patients with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older with HO. Patients will take an ora...
What is the current status of trial NCT06046443?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-07-11. Estimated completion is 2026-02-09.
What interventions are being tested in trial NCT06046443?
The interventions under investigation include: Placebo (DRUG), LB54640 (DRUG).
Who is sponsoring clinical trial NCT06046443?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.